肾衰营养胶囊通过Pfkfb3-MCTs糖酵解途径调控CKD-PEW骨骼肌萎缩的作用及机制
批准号:
82104795
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
胡蓉
依托单位:
学科分类:
中医内科学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
胡蓉
中文摘要
蛋白质能量消耗(PEW)是慢性肾脏病(CKD)常见的并发症。骨骼肌萎缩是其主要病理表现,严重增加CKD患者死亡率。最新研究发现:糖酵解代谢调节肌卫星细胞(MuSCs)功能是PEW骨骼肌萎缩的关键机制。肾衰营养胶囊是临床治疗CKD-PEW的经验方,疗效显著。课题组最新RNA-seq结果发现,肾衰营养胶囊促进MuSCs分化改善骨骼肌萎缩,可能与Pfkfb3、MCTs等基因有关。故本课题拟明确肾衰营养胶囊疗效,构建Pfkfb3特异性敲除小鼠和Pfkfb3 AAV过表达小鼠,探究Pfkfb3介导糖酵解途径对MuSCs功能及PEW骨骼肌萎缩的影响。再通过肾衰营养胶囊和Pfkfb3抑制剂干预CKD小鼠,反向验证复方的作用靶点。最终阐明肾衰营养胶囊通过Pfkfb3-MCTs糖酵解途径调控PEW骨骼肌萎缩的作用机制。为骨骼肌萎缩机制发掘新的突破口,也为证明中医药良好临床疗效提供可靠的科学依据。
英文摘要
Protein energy expenditure (PEW) is a common complication of chronic kidney disease (CKD). Skeletal muscle atrophy is the main pathological manifestation, which affects the long-term prognosis and mortality of CKD patients. The latest research found that glycolytic metabolism regulating muscle satellite cell (MuSCs) function is a key mechanism of skeletal muscle regeneration in PEW. Protein energy expenditure (PEW) is a common complication of chronic kidney disease (CKD). Skeletal muscle atrophy is the main pathological manifestation, and it will seriously increase the mortality of CKD patients. The latest research found that glycolytic metabolism regulating muscle satellite cell (MuSCs) function is the key mechanism of skeletal muscle atrophy in PEW. Shenshuai Nutrition Capsule is an effective empirical prescription for clinical treatment of CKD-PEW. Our lasted RNA-seq result found that Shenshuai Nutrition Capsule can promote the differentiation of MuSCs and alleviate skeletal muscle atrophy in PEW, which may be related to the level of metabolic genes such as Pfkfb3 and MCTs. Therefore, Pfkfb3 skeletal muscle-specific knockout and Pfkfb3 AAV overexpressed mice are constructed to investigate the effect and mechanism of Pkfb3-MCTs metabolic pathway on PEW skeletal muscle regeneration. Besides, Shenshuai Nutrition Capsule and Pfkfb3 inhibitor are used in CKD mice to verify the target genes. Finally, it is clarified that the Pfkfb3-MCTs glycolysis pathway is the mechanism of the Shenshuai Nutrition Capsules in PEW muscle regeneration. The research is a new breakthrough in the mechanism of skeletal muscle atrophy, and it provides a reliable scientific basis for proving the good clinical efficacy of Chinese medicine.
蛋白质能量消耗(PEW)是慢性肾脏病(CKD)常见的并发症。骨骼肌萎缩是PEW主要病理表现和诊断指标,直接影响CKD患者的远期预后和死亡率。前期研究提示糖酵解代谢途径可通过代谢产物乳酸及表观遗传改变调节MuSCs增殖分化功能,可能是PEW骨骼肌损伤后再生修复障碍的核心机制。肾衰 营养胶囊是临床治疗CKD-PEW的有效经验方,已获国家发明专利。本项目研究发现:肾衰营养胶囊能有效改善CKD大鼠肾功能,降低CKD大鼠血Scr、BUN和24小时尿蛋白水平,提高Alb水平;可增加CKD大鼠体重及骨骼肌质量,增加CKD大鼠骨骼肌横截面积,减轻CKD大鼠凋亡及自噬、线粒体损伤。转录组结果显示其作用机制涉及到Pfkfb3、MCTs糖酵解代谢途径、MRFs骨骼肌分化相关转录因子和PI3K-AKT等信号通路。此外,本项目成功构建Pfkfb3骨骼肌内皮细胞特异性敲除小鼠。结果发现,与,Pfkfb3 WT组相比,Pfkfb3ERT小鼠体重和骨骼肌质量下降,凋亡增多。HE染色结果显示,Pfkfb3ERT组小鼠肌纤维平均横截面积小于WT组,线粒体损伤增加;Pfkfb3ERT小鼠乳酸、PFK2、HK2、MCT1、MCT4、Pfkfb3等水平下降,WB结果显示Pfkfb3ERT小鼠MyoD1、Myf5、Myf6表达水平较WT组明显下调,骨骼肌分化和修复能力减弱。最后,通过灌胃PFKFB3抑制剂,结果表明:与肾衰营养胶囊组大鼠比较,加入PFKFB3抑制剂大鼠肌纤维横截面积减少;且MyoD1、Myf5、Pfkfb3、MCT4表达量下调,以上结果表明:肾衰营养胶囊通过Pfkfb3-MCTs调控骨骼肌分化,促进再生修复以改善骨骼肌萎缩。该项目为完善CKD-PEW骨骼肌萎缩病理机制提供了新的思路,并为中医药良好疗效提供充分可靠的科学依据。
肾衰营养胶囊通过Activin A调节肾-骨
骼肌交互轴改善CKD-PEW的作用及机制
-
批准号:--
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:胡蓉
-
依托单位:
国内基金
海外基金